Low PTEN Levels and PIK3CA Mutations Predict Resistance to Neoadjuvant Lapatinib and Trastuzumab without Chemotherapy in Patients with HER2 Over-Expressing Breast Cancer

PURPOSE: Aberrant activation of the PI3K pathway has been implicated in resistance to HER2 targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in breast cancers from patients treated wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Rimawi, Mothaffar F., De Angelis, Carmine, Contreras, Alejandro, Pareja, Fresia, Geyer, Felipe C., Burke, Kathleen A., Herrera, Sabrina, Wang, Tao, Mayer, Ingrid A, Forero, Andres, Nanda, Rita, Goetz, Matthew P., Chang, Jenny C., Krop, Ian E., Wolff, Antonio C., Pavlick, Anne C., Fuqua, Suzanne A. W., Gutierrez, Carolina, Hilsenbeck, Susan G., Li, Marilyn M., Weigelt, Britta, Reis-Filho, Jorge S., Osborne, C. Kent, Schiff, Rachel
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5821069/
https://ncbi.nlm.nih.gov/pubmed/29110152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4533-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados